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ターンから乳癌を分類した intrinsic subtype 分類の中で，
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ネガティブ乳癌のなかで basal phenotype を示す乳癌で
は non-basal phenotype と比べて腫瘍径が大きく，核グ
レードや EGFR 陽性率が高かった。また，basal pheno-
type を示す乳癌では non-basal phenotype と比べて有意
差は見られなかったが，早期に再発を認める傾向を示し
た。
２．intrinsic サブタイプ分類における basal-like type











































また，新たな intrinsic サブタイプとして claudin-low
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学で分類した basal phenotype を示す乳癌については一
定した結果が得られていない。これは，免疫組織化学に













































BL１: basal-like１, BL２: basal-like２, BLIS : basal-like immunosuppressed, BLIA : basal-like immune-activated,
LAR : luminal androgen receptor, TNBC : triple negative breast cancer
































１）Cancer Genome Atlas Network : Comprehensive
molecular portraits of human breast tumours. Nature，
４９０：６１‐７０，２０１２
２）Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall,
R. J., et al . : BRCA１ dysfunction in sporadic basal-
like breast cancer. Oncogene.，２６：２１２６‐２１３２，２００７









et al . : Clinical and pathologic characteristics of pati-
ents with BRCA-positive and BRCA-negative breast
cancer. J. Clin. Oncol.，２６：４２８２‐４２８８，２００８
４）Nagle, R. B., Bocker, W., Davis, J. R., Heid, H. W., et
al . : Characterization of breast carcinomas by two
monoclonal antibodies distinguishing myoepithelial
from luminal epithelial cells. J. Histochem. Cyto-
chem.，３４：８６９‐８８１，１９８６
５）Otterbach, F., Bankfalvi, A., Bergner, S., Decker, T.,
et al . : Cytokeratin ５／６ immunohistochemistry assi-
sts the differential diagnosis of atypical proliferations
of the breast. Histopathology.，３７：２３２‐２４０，２０００
６）Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S.,
et al . :Phenotypic evaluation of the basal-like subtype
of invasive breast carcinoma. Mod. Pathol.，１９：２６４‐
２７１，２００６
７）Cakir, A., Gonul, II., Uluoglu, O. : A comprehensive
morphological study for basal-like breast carcinomas
with comparison to nonbasal-like carcinomas. Diagn.
Pathol.，７：１４５，２０１２
８）Sasa, M., Bando, Y., Takahashi, M., Hirose, T., et al . :
Screening for basal marker expression is necessary
for decision of therapeutic strategy for triple-nega-
tive breast cancer. J. Surg. Oncol.，９７：３０‐３４，２００８
９）Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M.,
et al . : Molecular portraits of human breast tumours.
Nature.，４０６：７４７‐７５２，２０００
１０）Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., et al . :
Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implica-
tions. Proc. Natl. Acad. Sci. U. S. A.，９８：１０８６９‐
１０８７４，２００１
１１）Hu, Z., Fan, C., Oh, D. S., Marron, J. S., et al . : The
molecular portraits of breast tumors are conserved
across microarray platforms. BMC Genomics.，７：
９６，２００６
１２）Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E.,
et al . : Identification of human triple-negative breast
cancer subtypes and preclinical models for selection
of targeted therapies. J. Clin. Invest.，１２１：２７５０‐
２７６７，２０１１
１３）Lehmann, B. D., Jovanovic, B., Chen, X., Estrada, M.
V., et al . : Refinement of Triple-Negative Breast Can-
cer Molecular Subtypes : Implications for Neoadju-
vant Chemotherapy Selection. PLoS One.，１１：
e０１５７３６８，２０１６
１４）Prat, A., Parker, J. S., Karginova, O., Fan, C., et al . :
Phenotypic and molecular characterization of the
claudin-low intrinsic subtype of breast cancer. Breast
Cancer Res.，１２：R６８，２０１０
１５）Lehmann, B. D., Pietenpol, J. A. : Identification and
use of biomarkers in treatment strategies for triple-
negative breast cancer subtypes. J. Pathol.，２３２：
１４２‐１５０，２０１４
１６）Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington,
K. R., et al . : Comprehensive genomic analysis iden-
tifies novel subtypes and targets of triple-negative
breast cancer. Clin. Cancer Res.，２１：１６８８‐１６９８，２０１５
１７）Ring, B. Z., Hout, D. R., Morris, S. W., Lawrence, K., et
al . : Generation of an algorithm based on minimal
gene sets to clinically subtype triple negative breast
cancer patients. BMC Cancer.，１６：１４３，２０１６
１８）Prat, A., Adamo, B., Cheang, M. C., Anders, C. K., et
al . : Molecular characterization of basal-like and non-
basal-like triple-negative breast cancer. Oncologist.，
１８：１２３‐１３３，２０１３
１９）Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., et
al . : Immunohistochemical and clinical characteriza-
tion of the basal-like subtype of invasive breast car-
cinoma. Clin. Cancer Res.，１０：５３６７‐５３７４，２００４
２０）Jumppanen, M., Gruvberger-Saal, S., Kauraniemi, P.,
Tanner, M., et al . : Basal-like phenotype is not asso-
ciated with patient survival in estrogen-receptor-
negative breast cancers. Breast Cancer Res.，９：R１６，
２００７
２１）Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A.,
Habashi, H. O., et al . : Triple-negative breast cancer :
distinguishing between basal and nonbasal subtypes.
Clin. Cancer Res.，１５：２３０２‐２３１０，２００９
２２）Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R.
D., et al . :Tailoring therapies‒improving the manage-
ment of early breast cancer : St Gallen International
Expert Consensus on the Primary Therapy of Early
Breast Cancer 2015. Ann. Oncol.，２６：１５３３‐１５４６，２０１５
２３）Curigliano, G., Burstein, H. J., Winer, E. P., Gnant, M.,
et al . : De-escalating and escalating treatments for
坂 東 良 美２６４
early-stage breast cancer : the St. Gallen Internatio-
nal Expert Consensus Conference on the Primary
Therapy of Early Breast Cancer２０１７. Ann. Oncol.，２８：
１７００‐１７１２，２０１７
２４）Nakagawa, M., Bando, Y., Nagao, T., Morimoto, M., et
al . : Expression of p５３, Ki‐６７, E-cadherin, N-cadherin
and TOP２A in triple-negative breast cancer. Anti-
cancer Res.，３１：２３８９‐２３９３，２０１１
２５）Denkert, C., Liedtke, C., Tutt, A., von Minckwitz, G. :
Molecular alterations in triple-negative breast cancer-
the road to new treatment strategies. Lancet.，３８９：
２４３０‐２４４２，２０１７
２６）Silver, D. P., Richardson, A. L., Eklund, A. C., Wang,
Z. C., et al . : Efficacy of neoadjuvant Cisplatin in
triple-negative breast cancer. J. Clin. Oncol.，２８：
１１４５‐１１５３，２０１０
２７）Robson, M., Im, S. A., Senkus, E., Xu, B., et al . : Olapa-
rib for Metastatic Breast Cancer in Patients with a
Germline BRCA Mutation. N. Engl. J. Med.，３７７：
５２３‐５３３，２０１７
２８）Rakha, E. A., Aleskandarany, M., El-Sayed, M. E.,
Blamey, R. W., et al . : The prognostic significance of
inflammation and medullary histological type in
invasive carcinoma of the breast. Eur. J. Cancer.，４５：
１７８０‐１７８７，２００９
２９）Denkert, C., Loibl, S., Noske, A., Roller, M., et al . :
Tumor-associated lymphocytes as an independent
predictor of response to neoadjuvant chemotherapy
in breast cancer. J. Clin. Oncol.，２８：１０５‐１１３，２０１０
３０）Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., et
al . : Atezolizumab and Nab-Paclitaxel in Advanced
Triple-Negative Breast Cancer. N. Engl. J. Med.，３７９：
２１０８‐２１２１，２０１８
トリプルネガティブ乳癌の多様性と病理診断 ２６５
Classification of triple-negative breast cancer subtypes based on heterogeneity and
comparison with basal-like carcinoma
Yoshimi Bando
Division of Pathology, Tokushima University Hospital, Tokushima, Japan
SUMMARY
Immunohistochemical and fluorescence in situ hybridization（FISH）methods have been imple-
mented to characterize triple negative breast cancer（TNBC）due to the lack of expression of es-
trogen receptor（ER）and progesterone receptor（PgR）as well as human epidermal growth factor
receptor２（HER２）. TNBC exhibits adverse prognostic features, as both hormone and anti-HER２
therapies are ineffective, and thus chemotherapy is required.
Among the intrinsic subtypes identified through gene expression analysis, the expression of ER
and HER２cluster was found to be low specifically in the basal-like subtype. The basal-like subtype
exhibits mammary myoepithelial cell（or basal cell）-like gene expression pattern. Most of the cells
were triple negative in immunohistochemical method, and exhibited a characteristic expression of
myoepithelial or basal cell markers, such as cytokeratin（CK）５／６, CK１４, CK１７, p６３, and epidermal
growth factor receptor（EGFR）. Basal-like carcinoma is similar to TNBC in terms of histology and
clinical features. Here, we have presented some of our study results indicating the characteristics of
TNBC and basal-like phenotype.
TNBC is a heterogeneous disease, and ongoing research is aimed at developing individualized
treatment based on its biological characteristics. However, the effective treatment methods and
therapeutic efficacy predictors are yet to be discovered. Recently, targeted therapies for TNBC,
including the poly（ADP-ribose）polymerase（PARP）inhibitors for germline BRCA mutation-
associated breast cancer and immune checkpoint inhibitors, have been approved. Moreover, the
level of programmed death ligand１（PD-L１）in tumor-infiltrating immune cells is determined using
the histopathological analysis of specimens to assess the effect of immune checkpoint inhibitors.
In this review, the classification of TNBC subtypes and characteristics of basal-like carcinoma
has been discussed.
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